Excerpts from an interview with MDRNA’s CEO
As I reported yesterday, Nastech Pharmaceutical -- now MDRNA Inc. -- appointed J. Michael French as its new CEO. French previously worked at Sirna Therapeutics as that company's senior vice president...
View ArticleCEO on Seattle Genetics’ deal-making, plans
For my story today on Seattle Genetics' deal with Daiichi Sankyo (Read it here) I talked to Seattle Genetics CEO Clay Siegall.
View ArticleHuntsman on the Life Sciences Discovery Fund
As I reported this morning, the Life Sciences Discovery Fund said today it would distribute $5.2 million to fund six projects. It was the group's second allocation of money this year. While the fund...
View ArticleZymoGenetics’ Bruce Carter on Recothrom
On Tuesday, ZymoGenetics underwhelmed Wall Street for the second straight quarter with lackluster sales numbers for its first drug, Recothrom. Read my story on that news here. After the company's...
View Article
